In a Phase I trial, 177Lu-FAPI-46 was administered to 18 patients with advanced, treatment-refractory FAP positive cancers, achieving stable disease in two-thirds of cases with minimal radiation to healthy tissues [187]. Here, FAP is linked to cancer.